Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 2;34(21):2460–2467. doi: 10.1200/JCO.2015.64.8931

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by American Society of Clinical Oncology

PMC Copyright notice

Fig 1. — Antitumor activity of pembrolizumab based on RECIST v1.1 assessed by central review. (A) Best percentage change from baseline in the sum of the longest diameters of target lesions. (B) Longitudinal change from baseline in the sum of the longest diameters of target lesions. (C) Time to and durability of response. For each panel, only patients who received at least one pembrolizumab dose and who had evaluable tumor measurements based on RECIST v1.1 assessed by central review at baseline and at least one postbaseline assessment were included (n = 24). Reasons for treatment discontinuation in patients whose change from baseline per RECIST v1.1 by central review was ≤ 20% are indicated; because patients were managed by investigator assessment, reasons for discontinuation are based on RECIST v1.1 by investigator review. In panel C, length of bars equals time to last imaging assessment by central review. RECIST, Response Evaluation Criteria in Solid Tumors.